Despite the encouraging findings of two phase I/II trials showing that the APR-246/azacitidine combination resulted in high response and complete-remission rates, as well as high rates of TP53-mutation clearance [170,171], the survival benefit of this combination over azacitidine alone for TP53-mutated high-risk MDS/AML-MRC has not been confirmed. This evidence concerns the gene TP53 and acute myeloid leukemia.